News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Daily News ‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF L.A. McKeown September 18, 2023
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Daily News US and European Valvular Guidelines Mostly Concordant, Analysis Finds L.A. McKeown August 21, 2023
News Opinion Editor's Corner ESC 2023 What’s Going to Be Hot at ESC 2023? Shelley Wood August 15, 2023
News Conference News ESOC 2023 ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy Todd Neale May 25, 2023
News Daily News RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads Todd Neale January 19, 2023
News Daily News Left Atrial Dysfunction Tied to Cerebral Infarcts in Absence of Prior AF, Stroke Todd Neale December 21, 2022
News Daily News OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer L.A. McKeown December 16, 2022
News Daily News Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS Todd Neale December 01, 2022
News Daily News Many ESC Guideline Recommendations Out of Reach in Poorer Regions Michael O'Riordan November 29, 2022
News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Conference News AHA 2022 ‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge L.A. McKeown November 11, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Daily News COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review Todd Neale October 12, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2022 Shelley Wood October 03, 2022